Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects

Drug Metabolism and Disposition

Volumn 27, Issue 7, 1999, Pages 810-815

  Weber, Cornelia ^a   Gasser, Rodolfo ^b   Hopfgartner, G ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Preclinical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CARBON 14; ENDOTHELIN RECEPTOR ANTAGONIST;

ARTICLE; BILIARY EXCRETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RECEPTORS, ENDOTHELIN; REFERENCE VALUES; SULFONAMIDES;

EID: 0032995719     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Benet LZ and Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68:1071-1074.
2. Clozel M, Breu V, Gray GA, Kalina B, Löffler B-M, Burn K, Cassal J-M, Hirth G, Müller M, Neidhardt W and Ramuz HJ (1994) Pharmacological characterisation of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Pharmacol Exp Ther 270:228-235.
3. Hopfgartner G, Chernuchevich I, Covey T and Bonner R (1998) Accurate mass measurements on product ions for structural elucidation of drug metabolites with tandem quadrupole TOF instruments. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, May 31-June 4, 1998.
4. Hopfgartner G, Vetter W, Meister W and Ramuz H (1996) Fragmentation of bosentan (Ro 47-0203) in ionspray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ion. J Mass Specirom 31:69-76.
5. Kiowski W, Suetsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones CR and Bertel O (1995) Evidence of endothelin-1 mediated vasoconstriction in severechronic heart failure. Lancet 346:732-736.
6. Krum H, Viskoper RJ, Lacourcierge Y, Budde M and Charlon V (1998) The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784-790.
7. Lausecker B, Hess B and Hopfgartner G (1998) Determination of a non-peptidic endothelin receptor antagonist Ro 47-0203 and its metabolites in different matrices from various species using HPLC ionspray MS/MS. Proceedings of the 46th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, FL, May 31-June 4, 1998.
8. Noll G, Wenzel RR and Luescher TF (1996) Endothelin and endothelin antagonists: Potential role in cardiovascular and renal disease. Mol Cell Biochem 157:259-267.
9. Suetsch G, Kiowski W, Van X-W, Hunziker P, Christen S, Trobel W, Kim J-H, Rickenbacher P and Bertel O (1998) Short-term endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98:2262-2268.
10. Ubeaud G, Schmitt C, Jaeck D, Lave T and Coassolo P (1995) Bosentan, a new endothelin-receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25:1381-1390.
11. Webb DJ, Monge JC, Rabelink TJ and Yanagisawa M (1998) Endothelin: New discoveries and rapid progress in clinic. Trends Pharmacol Sci 19:5-8.
12. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, Jonkman JHG and Jones CR (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124-137.
13. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond) 332:411-415.